HDAC9 and Miyoshi myopathy: For example, while the HDAC inhibitor panobinostat does not show single agent activity in MM, it however enhances the efficacy of the proteasome inhibitor bortezomib in this setting, a DTT regimen approved to treat relapsed MM.